Recommended Workup and Treatment for Newly Diagnosed Urothelial Carcinoma
For newly diagnosed urothelial carcinoma, immediately stage the disease through cystoscopy with biopsy and cross-sectional imaging (CT urography or MR urography), then stratify treatment based on whether disease is non-muscle-invasive (70% of cases), muscle-invasive (25%), or metastatic/advanced (5%) 1.
Initial Diagnostic Workup
Perform the following staging evaluation:
- Cystoscopy with transurethral resection of bladder tumor (TURBT) for tissue diagnosis and local staging
- CT urography or MR urography to evaluate upper tracts and detect metastatic disease
- Chest imaging to rule out pulmonary metastases
- Assess renal function (creatinine clearance/GFR) to determine cisplatin eligibility
- Performance status evaluation (ECOG) to guide treatment intensity
For upper tract disease specifically, diagnostic ureteronephroscopy with biopsy is essential 2.
Treatment Algorithm by Stage
Non-Muscle-Invasive Disease (Ta, T1, CIS)
Transurethral resection followed by single intravesical chemotherapy instillation within 24 hours reduces recurrence risk significantly 1.
For high-grade disease or CIS:
- Intravesical BCG immunotherapy (standard of care)
- Close surveillance due to 31-78% recurrence rate within 5 years
Muscle-Invasive Disease (T2-T4a, N0-N1)
Radical cystectomy with extended pelvic lymph node dissection remains the gold standard 1, 3.
Neoadjuvant cisplatin-based chemotherapy before cystectomy improves survival and should be offered to eligible patients 1.
Alternative for select patients:
- Trimodality bladder-preserving therapy (maximal TURBT + concurrent chemoradiotherapy) for solitary T1-T2 tumors <5 cm 4
Advanced/Metastatic Disease (T4b, N2-N3, M1)
This is where treatment paradigms have evolved dramatically and require careful algorithmic decision-making.
First-Line Treatment for Advanced Disease
For Cisplatin-Eligible Patients
Enfortumab vedotin + pembrolizumab is now the preferred first-line regimen, showing superior outcomes with median OS of 31.5 months versus 16.1 months with chemotherapy alone (HR 0.47) 2.
Alternative first-line options for cisplatin-eligible patients:
- Nivolumab + gemcitabine/cisplatin followed by nivolumab maintenance (median OS 21.7 vs 18.9 months; HR 0.78) - this is a category 1 recommendation 5
- Gemcitabine/cisplatin alone (median OS ~13 months) 1
- Dose-dense MVAC with growth factor support
For Cisplatin-Ineligible Patients
First, determine if the patient has high PD-L1 expression using companion diagnostic testing 3, 6, 3.
If PD-L1 positive (≥5% tumor-infiltrating immune cells for atezolizumab OR combined positive score ≥10 for pembrolizumab):
If PD-L1 negative OR not eligible for any platinum therapy:
- Gemcitabine/carboplatin combination 1
Critical caveat: FDA issued safety alerts in 2018 showing decreased survival with first-line checkpoint inhibitor monotherapy in PD-L1 low patients compared to chemotherapy. This restriction is based on early data from KEYNOTE-361 and IMvigor-130 trials 3, 6.
Second-Line and Subsequent Therapy
Treatment sequencing depends heavily on prior therapy received.
After Platinum-Based Chemotherapy (No Prior Checkpoint Inhibitor)
Pembrolizumab is the only category 1 recommendation based on phase III KEYNOTE-045 data showing median OS of 10.3 vs 7.4 months compared to chemotherapy (HR for death 0.73, p=0.002), with significantly fewer grade ≥3 adverse events (15% vs 49.4%) 3, 7.
Alternative checkpoint inhibitors (all category 2):
- Atezolizumab
- Nivolumab
- Durvalumab
- Avelumab
These agents show response rates of 15-29% in the post-platinum setting but lack phase III survival data 3, 7.
After Both Platinum and Checkpoint Inhibitor Therapy
Enfortumab vedotin is the preferred option, showing 40-44% response rates in heavily pretreated patients 3.
For patients with FGFR2/3 mutations or FGFR3 fusions: Erdafitinib demonstrates superior outcomes with median OS of 12.1 vs 7.8 months compared to chemotherapy (HR 0.64, p=0.005) in the phase III THOR trial 5. Genomic testing for FGFR alterations is essential to identify these patients.
For HER2-overexpressing tumors: Trastuzumab deruxtecan is now an option 4.
Third-Line and Beyond
Options include:
- Vinflunine (if not previously used)
- Single-agent chemotherapy (docetaxel, paclitaxel, gemcitabine)
- Clinical trial enrollment (strongly recommended) 3
Key Clinical Pitfalls to Avoid
Do not use first-line checkpoint inhibitor monotherapy in cisplatin-ineligible patients with low PD-L1 expression - this shows worse survival than chemotherapy 6.
Assess cisplatin eligibility carefully using established criteria: adequate renal function (GFR ≥60 mL/min), ECOG performance status 0-1, no significant hearing loss, no heart failure, and no peripheral neuropathy 1, 2.
Obtain FGFR and HER2 testing early in metastatic disease to identify patients eligible for targeted therapies in later lines 4, 5.
Consider neoadjuvant chemotherapy before cystectomy in muscle-invasive disease - this improves survival but is often underutilized 1.
Recognize that approximately 40% of patients are cisplatin-ineligible at diagnosis, requiring alternative treatment algorithms 1.
Survival Expectations
- Non-muscle-invasive disease: Generally favorable with appropriate treatment
- Muscle-invasive disease: 5-year survival improves with multimodal therapy
- Metastatic disease with standard chemotherapy: Median OS ~13 months 1
- Metastatic disease with modern immunotherapy combinations: Median OS now exceeding 20-31 months 1, 2, 5
- Post-platinum progression without further therapy: Median survival 5-7 months 3
The treatment landscape has fundamentally shifted with enfortumab vedotin + pembrolizumab and checkpoint inhibitor combinations now offering substantially improved survival compared to historical chemotherapy-only approaches 2, 5.